HARROW INC (HROW) Stock Price, Forecast & Analysis
NASDAQ:HROW • US4158581094
HROW Key Statistics, Chart & Performance
The current stock price of HROW is 50.4146 USD. In the past month the price increased by 5.51%. In the past year, price increased by 74.58%.
HROW Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to HROW. When comparing the yearly performance of all stocks, HROW is one of the better performing stocks in the market, outperforming 92.42% of all stocks.
HROW Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to HROW. Both the profitability and the financial health of HROW get a neutral evaluation. Nothing too spectacular is happening here.
HROW Financial Highlights
Over the last trailing twelve months HROW reported a non-GAAP Earnings per Share(EPS) of 0.09. The EPS increased by 109.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.37% | ||
| ROE | -10.6% | ||
| Debt/Equity | 5.17 |
HROW Forecast & Estimates
14 analysts have analysed HROW and the average price target is 72.13 USD. This implies a price increase of 43.07% is expected in the next year compared to the current price of 50.4146.
For the next year, analysts expect an EPS growth of 122.31% and a revenue growth 39.67% for HROW
HROW Ownership
HROW Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.37 | 979.461B | ||
| JNJ | JOHNSON & JOHNSON | 20.91 | 586.255B | ||
| MRK | MERCK & CO. INC. | 22.3 | 301.739B | ||
| PFE | PFIZER INC | 9.13 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.84 | 122.858B | ||
| ZTS | ZOETIS INC | 18.72 | 55.333B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.212B | ||
| VTRS | VIATRIS INC | 6.28 | 18.129B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.01 | 12.352B | ||
| AXSM | AXSOME THERAPEUTICS INC | 225.4 | 9.24B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About HROW
Company Profile
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Company Info
HARROW INC
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE 37205 US
CEO: Mark L. Baum
Employees: 382
Phone: 16157334731
HARROW INC / HROW FAQ
Can you describe the business of HARROW INC?
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The company offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
Can you provide the latest stock price for HARROW INC?
The current stock price of HROW is 50.4146 USD. The price decreased by -0.25% in the last trading session.
What is the dividend status of HARROW INC?
HROW does not pay a dividend.
What is the ChartMill technical and fundamental rating of HROW stock?
HROW has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is HARROW INC (HROW) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on HROW.
Can you provide the growth outlook for HARROW INC?
The Revenue of HARROW INC (HROW) is expected to grow by 39.67% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of HROW stock?
HARROW INC (HROW) has a market capitalization of 1.87B USD. This makes HROW a Small Cap stock.